Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.54 |
| ▸ | F2 | P00734 | 11/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 8/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 8/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | F9 | P00740 | 2/20 | 0.41 |
| ▸ | PROC | P04070 | 2/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | CFH | P08603 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360886 | 0.91 | F10 (0.56) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6361214 | 0.89 | F10 (0.52) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6358733 | 0.86 | F10 (0.57) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6359313 | 0.86 | F10 (0.51) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6357592 | 0.84 | F10 (0.55) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6363463 | 0.81 | F10 (0.44) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6360228 | 0.81 | F10 (0.55) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6360233 | 0.79 | F10 (0.56) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6223388 | 0.78 | F10 (0.53) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6359487 | 0.77 | F10 (0.53) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119316-A1 | Semicarbazide derivatives and the use thereof as antithrombotics | MERCH PATENT GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1480948-A1 | SEMICARBAZIDE DERIVATIVES AND THEIR USE AS ANTITHROMBOTICS | MERCK PATENT GmbH (DE) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074479-A1 | SEMICARBAZIDE DERIVATIVES AND THEIR USE AS ANTITHROMBOTICS | MERCK PATENT GMBH (DE) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119316-A1 | Semicarbazide derivatives and the use thereof as antithrombotics | SERPINC1, F12, F11 | F10 13/4885F2 10/4885PRSS1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.